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Introduction
Resistance to antimicrobial drugs threatens incremental 
gains that have been made in the global fight against tuber-
culosis. It has been estimated that 480 000 people develop 
multidrug-resistant (MDR) tuberculosis each year.1 In 2013, 
only 20% of these people received recommended second-
line treatment regimens; yet only about 50% of the people 
that did receive such regimens had successful treatment 
outcomes.1 Therefore, most people with MDR tuberculosis 
transmit drug-resistant Mycobacterium tuberculosis to other 
members of their communities, since they go undiagnosed 
or are diagnosed but only treated with ineffective first-line 
drugs.2 There is an urgent need for accessible and improved 
treatments for MDR tuberculosis – to reduce mortality and 
avoid scenarios in which resistance becomes the norm rather 
than the exception. There needs to be a major scale-up of 
treatment for MDR tuberculosis that matches the scale-ups 
that have already been achieved in treatments for human 
immunodeficiency virus and drug-susceptible tuberculosis. 
The decentralization of diagnosis, care and management is 
essential. Specialist medical management needs to be largely 
replaced by nurse-led care, with hospitalization restricted to 
those patients for whom it is medically indicated. Treatment 
regimens need to be simplified, shortened and improved, so 
that treatment success exceeds 50%.1
After more than 40 years without any new tuberculosis 
drugs, there are now several new drugs that are in develop-
ment or becoming available.3 Examples include bedaquiline 
– which received conditional approval from the United States’ 
Food and Drug Administration in December 2012 and con-
ditional marketing authorization by the European Medicines 
Agency in December 2013 – and delamanid – which received 
conditional authorization by the European Medicines Agency 
in April 2014. In phase II trials – compared with a placebo 
and within an optimized background regimen – both of these 
drugs appeared to be efficacious against MDR tuberculosis.4,5 
Phase III trials of these drugs are planned or underway. Some 
so-called repurposed drugs – e.g. linezolid, which has been 
primarily used for the treatment of Gram-positive bacterial 
infections – also appear to be promising in the treatment of 
MDR tuberculosis.6
Despite this apparent progress, access to new or repur-
posed drugs is associated with substantial challenges for the 
majority of patients in settings with high burdens of MDR 
tuberculosis.7 In addition to regulatory approval in Europe and 
the United States of America, specific country-level regulatory 
approval is often required and can be difficult to obtain. The 
level of difficulty depends mainly on the sophistication of na-
tional intellectual property laws and the regulatory authorities. 
After approval of a new treatment has been granted, national 
programmes often grapple with issues of cost and supply and 
require guidance on appropriate use. In general, such pro-
grammes rely on the World Health Organization (WHO) for 
policy recommendations. Guidance on the appropriate use of 
new drugs for MDR tuberculosis is currently constrained by 
limitations in the available evidence, which is often entirely 
based on the results of phase II and phase III trials in which 
the efficacies of current regimens with and without a new 
drug were compared. Much of the available guidance on the 
optimal use of new or repurposed drugs continues to rely on 
expert opinion. We need innovative and rigorous observational 
studies to be run concurrently with – and complementary to – 
randomized controlled trials. Such studies should be designed 
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to investigate the incorporation of new 
drugs into more tolerable and practi-
cable regimens and to evaluate the novel 
regimens under routine conditions.
Tolerability and practicality
Clinical trials are designed to dem-
onstrate the new drug’s efficacy and 
safety, for the purposes of obtaining 
drug approval and registration. They 
are not designed to identify the best 
possible treatment regimen to achieve 
large-scale effectiveness. The approach 
followed in clinical trials of bedaquiline 
and delamanid – i.e. adding either drug 
to an existing, long, toxic, complex regi-
men – is extremely unlikely to improve 
treatment access or patient outcomes 
substantially. Although inclusion of 
bedaquiline or delamanid has led to 
improved culture conversion, it has not 
led to overall treatment success levels 
that were substantially greater than 
those reported, in systematic reviews, 
for the currently recommended treat-
ment regimens for MDR tuberculosis.4,5,8
Use of the currently recommended 
regimens is plagued by poor uptake 
and poor results.1 The large pill burden, 
treatment side-effects and the need for 
daily injections and routine, long-term 
hospitalization all lead to high demands 
on both patients and health systems. 
As a result, early discontinuation of 
treatment is consistently above 20% of 
patients in many settings and up to 52% 
in some settings.1,9
Compared with any currently rec-
ommended regimen, a better-tolerated 
regimen that can be administered in 
decentralized settings by the existing 
tuberculosis programmes should en-
hance treatment uptake and completion 
and have a greater impact. An entirely 
oral regimen – i.e. one that obviates the 
need for painful, daily injections admin-
istered by health workers – would have 
the combined benefits of improving ad-
herence and treatment completion while 
reducing severe and debilitating adverse 
events10 and reducing the demands on 
the health system.
There is a clear need for innovative 
treatment regimens that incorporate 
new or repurposed drugs or older 
drugs in novel combinations that can 
be used in shorter treatment regimens. 
The focus of improvements needs to be 
broadened beyond efficacy and safety to 
the capacity to scale-up treatment and 
reach a much larger proportion of the 
disease burden with a better-tolerated 
and practical regimen. This approach 
is relevant for both clinical trials and 
innovative operational research.
Clinical trials
The limitations of currently recom-
mended treatment regimens for MDR 
tuberculosis are largely due to the regi-
mens’ dependence on old drugs, the use 
of which is generally poorly supported 
by evidence. It is noteworthy that most 
companion drugs for such tuberculosis 
are used off-label (in a manner that, 
according to the drug’s label, is not 
formally approved). In contrast to the 
treatment of drug-susceptible tubercu-
losis, there have been no clinical trials to 
guide the design of treatment regimens 
for MDR tuberculosis. Consequently, 
drugs have been combined into treat-
ment regimens for MDR tuberculosis 
based only on expert opinion and ob-
servational experience obtained over the 
past 15 years.11 In this context, clinical 
trials are much-needed.
A phase III trial testing delamanid 
against placebo is underway, with results 
expected by 2017.12 Both treatment and 
placebo arms of the trial receive an 
optimized background treatment regi-
men. The United States Food and Drug 
Administration approved bedaquiline 
under the condition that a phase III 
trial of the drug be completed by 2022.13 
Instead of conducting a separate phase 
III trial, there are plans to incorporate 
an entirely oral, bedaquiline-containing 
arm into an existing study (STREAM), 
which is examining shorter nine-month 
regimens using existing and repurposed 
drugs.14
In addition to the bedaquiline-
containing arms in STREAM, a small 
number of trials that aim to test combi-
nations of new, repurposed and existing 
drugs for MDR tuberculosis are being 
planned. Médecins Sans Frontières, 
Partners in Health and other groups 
are planning a set of clinical trials, 
using adaptive approaches, to design 
new regimens containing bedaquiline, 
delamanid and/or the nitroimidazole 
PA-824 and create shorter, better-
tolerated and more effective regimens 
that have the potential to increase access 
to treatment in a range of settings.15 The 
Global Alliance for TB Drug Develop-
ment is implementing a small one-arm 
study – the so-called Nix-TB trial – to 
assess a regimen that contains all the 
new drugs for extensively drug-resistant 
tuberculosis.16 The Global Alliance also 
plans to enrol a small number of MDR 
tuberculosis patients in a trial to test a 
combination of PA-824, moxifloxacin 
and pyrazinamide.17 Unfortunately, the 
AIDS Clinical Trials Group’s plans for a 
trial of new regimens for MDR tubercu-
losis17 ended in June 2014.
With the exception of the Nix-TB 
trial, none of the remaining trials that 
we have mentioned has obtained full 
approval for implementation or started 
recruiting patients. Trials to investigate 
combinations of bedaquiline and dela-
manid are contingent on the results of 
a study of drug–drug interaction and 
safety of the drugs in combination, 
planned by the United States National 
Institutes of Health. Although the fast-
tracking of this study has been recom-
mended, it remains in preparation and 
patient recruitment is unlikely to start 
before late 2015.18 Trials combining 
bedaquiline with PA-824 are also on 
hold until the safety of the combination 
can be assessed in the Nix-TB trial. In 
addition to the delays in planning and 
implementing clinical trials, clinical tri-
als for tuberculosis are extremely slow. 
The results of recent tuberculosis trials 
have only been released 6–9 years after 
the first patient was allocated to a treat-
ment arm.19–21
Even if the limited number of tri-
als currently in process and planning 
produce promising results, it is unlikely 
that we will have data to guide regimen 
formulation for programmatic use until 
at least 2020. Given the urgent need for 
expanded and improved MDR tuber-
culosis treatment, this timeline appears 
untenable.
Policy guidance
WHO released interim policy guid-
ance for the use of bedaquiline in June 
2013.22 Given the limited data available, 
WHO recommended that bedaquiline 
be restricted to tuberculosis patients 
showing extensive drug resistance and 
a poor response to their current treat-
ment and to patients affected by adverse 
events that limit the options for treat-
ment with other drugs. WHO released 
guidance on the use of delamanid in 
November 2014.23 For delamanid, WHO 
made similar recommendations as for 
bedaquiline but also suggested that use 
of delamanid may not be warranted in 
situations where an effective regimen 
can be composed of older drugs. Given 
the lack of data on the concurrent use of 
delamanid and bedaquiline, WHO felt 
Bull World Health Organ 2015;93:491–497| doi: http://dx.doi.org/10.2471/BLT.14.138925 493
Policy & practice
Access to new drugs for multidrug-resistant tuberculosisHelen S Cox et al.
unable to make any recommendations 
on the joint administration of the two 
drugs. WHO has, however, released 
general guidance on the introduction of 
new tuberculosis drugs.24 The guidance 
from WHO is important for national 
programmes that need to decide how 
best to utilize the new drugs. However, 
restricting access to new drugs to specif-
ic patient groups in approved, specialist 
centres – as is currently recommended 
– fails to meet the need in tuberculosis 
programmes around the world, where 
the current availability of treatment for 
MDR tuberculosis is often very limited .
Bedaquiline is becoming – and 
delamanid will probably soon become 
– increasingly available globally. There 
will soon be growing pressure from 
clinicians and patients to expand use of 
both drugs to cover a greater proportion 
of patients with drug-resistant tubercu-
losis, both to improve treatment and, 
potentially, to reduce the side-effects 
of treatment. The demand for MDR 
tuberculosis treatment is also likely to 
increase dramatically as countries ex-
pand the use of rapid diagnostic tests.25 
The fact that patients with drug-resistant 
tuberculosis in low-burden but high-
resource settings are likely to gain access 
to new drugs will also influence demand. 
As a result, it is inevitable that both 
bedaquiline and delamanid will be used 
in the field to replace existing drugs in 
a regimen and/or to shorten treatment.
Given the delay in accumulating 
clinical trial evidence, alternative data to 
inform the optimal, interim use of these 
new drugs is required. Such data should 
increase access to treatment while con-
tributing to the evidence base on use 
of the new drugs in the settings where 
treatment is most needed. Evidence 
could be appropriately incorporated into 
policy recommendations by WHO and 
programmatic decisions by countries.
Operational research
Over the past decade, considerable 
insights have been made into the de-
velopment of drug resistance during 
tuberculosis treatment, along with a 
greater understanding of the role of 
pharmacokinetics and drug syner-
gies.26–28 These insights have contrib-
uted to choices of drug combinations 
and regimens that have recently been 
taken into preclinical studies and clini-
cal trials.29 This knowledge can also be 
used to guide the incorporation of new 
drugs into existing treatment regimens 
under operational research conditions, 
while reflecting specific disease burdens 
and health system realities. Relatively 
short (nine- to 10-month) treatment of 
MDR tuberculosis with existing drugs, 
based on the regimen already used in 
Bangladesh,30 is currently being as-
sessed in several settings as well as in 
the STREAM trial. Such short regimens 
have produced excellent outcomes 
under operational research conditions 
in some settings31,32 and may be scaled 
up before the results of the formal 
STREAM trial become available. Since 
the operational research approach to the 
investigation of existing drugs, as sup-
ported by WHO, encompasses ethical 
review and close monitoring of patients, 
it could make valuable contributions to 
the evidence base.33
While not using the rigid standards 
of clinical management and reporting 
required for clinical trials, observational 
studies can provide a better quality 
of care than that available in routine 
treatment. In order for observational 
studies to maximize patient safety and 
provide quality data, they should in-
clude: (i) assured access to laboratory 
and clinical tests, for safety assessment; 
(ii) strong community-based follow-
up, to allow for proactive monitoring 
of patient outcomes; and, ideally, (iii) a 
standardized tool for the collection of 
basic safety and efficacy data (Box 1). 
While the number of patients included 
in clinical trials – after satisfying mul-
tiple criteria for eligibility – is often in 
the hundreds, operational studies can 
aim to treat all diagnosed cases within 
certain geographical regions and po-
tentially offer treatment to thousands 
of patients. Instead of the complexities 
of randomization to different regimens, 
all patients can be treated with the same 
regimen. Observational studies can 
also build local clinical capacity and 
strengthen health systems – two key 
prerequisites for treatment scale-up and 
continued research.
Risks and benefits
Treatment as prevention has the dual 
aims of reducing mortality and inter-
rupting disease transmission. The 
benefits and risks of accelerated access 
to new drugs – potentially leading to a 
greater proportion of patients receiv-
ing treatment and a greater treatment 
success – can be compared with those 
achieved through a more restricted and 
gradual introduction. For example, if 
the incidence of MDR tuberculosis stays 
the same for another decade, 4.8 million 
patients will develop MDR tuberculosis.1 
Doubling access to treatment from the 
current level of 20% of patients, and 
increasing treatment success to 80% 
Box 1. Development of new regimens for the treatment of multidrug-resistant 
tuberculosis via large-scale operational research projects
Key aspects of projects
• Can include all patients with tuberculosis, including children and those with human 
immunodeficiency virus infection.
• Aim to increase access to effective care.
• Can employ algorithmic approaches to treatment, based on setting-specific access to 
diagnostics and drug susceptibility testing.
• Can employ individualized treatment to varying extents, dependent on health system 
constraints and disease burden.
• Aim to enhance health system capacity to diagnose and treat tuberculosis, including 
enhancement of routine monitoring of treatment and patient outcomes.
• Can collect data in a thorough and compatible fashion, to inform global policy.
Proposed requirements
• Ethical review and oversight to maintain patient safety and clinical standards.
• Treatment delivery following principles of good clinical practice.
• Clear criteria for treatment provision.
• Access to laboratory and clinical tests – i.e. complete blood cell counts, liver function tests 
and electrocardiograms – for safety assessment.
• Access to trained providers, not necessarily on-site, to interpret and advise on test results.
• Proactive monitoring through community-based care.
• Compatible tools for safety and efficacy monitoring and reporting.
• Communication channels for rapid dissemination of results between operational research 
sites.
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would result in cure for more than a 
million additional patients over the next 
decade (Fig. 1). Given 80% treatment 
success, tripling access could save 1.8 
million lives over the same period. The 
aim should not be to limit access to new 
drugs but to facilitate access in a manner 
that provides the greatest benefit while 
minimizing risk.
Several researchers have expressed 
concern that the scaled-up use of new 
drugs will lead to the rapid develop-
ment of widespread resistance to the 
drugs.34,35 This concern motivates ef-
forts to restrict the use of new drugs 
to small, well-functioning programmes 
and to use very restrictive criteria for 
patient eligibility. Current policies 
emphasize minimizing the risk of wide-
spread resistance. However, this risk 
needs to be carefully weighed against 
the deaths that might be expected un-
der different scale-up scenarios. The 
development of resistance to drugs used 
to treat tuberculosis and all other infec-
tious diseases is inevitable. Resistance 
to almost every antimicrobial in clinical 
use has been detected.36 Although re-
sistance to some tuberculosis drugs has 
emerged rapidly, the mechanisms and 
drivers of such resistance remain poorly 
understood.37–40 It also remains unclear 
if restricting access to a drug slows 
the acquisition of resistance to that 
drug.26,41 The acquisition of resistance 
to the drugs used in the second-line 
treatment of tuberculosis appears to be 
driven by regimen composition, such 
that the risk of such resistance increases 
substantially as the number of effective 
drugs in the regimen decreases.42 The 
acquisition of resistance was found to 
be relatively rare in programmes ap-
proved by the Green Light Committee 
Initiative, probably as the result of strict 
regimen guidance.42 Accelerating access 
to new drugs – contained in improved, 
easier-to-administer regimens – may 
actually reduce the rate at which resis-
tance develops. If treatment outcomes 
can be improved and the number of 
patients managed by a nurse or other 
health-care worker can be increased 
by the use of simplified, less toxic 
regimens, the encouraging results seen 
in programmes approved by the Green 
Light Committee Initiative ought to be 
achievable on a much larger scale.
Finally, the safety of a treatment 
regimen is considered paramount. 
The maxim of first do no harm can 
lead to a drug not being used because 
of rare, but serious, risks to patients. 
In the case of MDR tuberculosis, no 
cardiac event has yet been attributed to 
the use of bedaquiline and delamanid, 
despite the knowledge that both drugs 
can prolong the QT interval. However, 
sudden death, deafness, renal insuf-
ficiency, psychosis and irreversible 
peripheral neuropathy are some of 
the known adverse effects of the older 
drugs still used.43–46
Conclusion
Although the development and approval 
of new drugs provide hope for the hun-
dreds of thousands of people affected 
by MDR tuberculosis each year, we still 
need to know how to use such drugs at 
scale in the most effective way. If we can 
rapidly develop a knowledge base on 
how to use new drugs in combination 
with existing drugs, we may soon be able 
to offer effective treatment to all those in 
need – and not just to those few patients 
who are able to access specialist care in 
well-resourced settings.
Scale-up of drug-resistant tuber-
culosis treatment has been singularly 
ineffective over the last decade. In the 
absence of innovative thinking, there is 
a danger that we will take a conservative 
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Notes: The numbers of patients that would occur over the decade that began on 1 January 2015 were 
estimated using two scenarios. In one – the baseline scenario – the percentage of people receiving the 
recommended treatment and having a successful treatment outcome were set at the values estimated 
for 2013: 20% and 10%, respectively.1 In the other, so-called accelerated access scenario, these values 
were increased to 40% and 32%, respectively, to model the possible effects of accelerated access to 
new drugs. In both scenarios it was assumed that 480 000 persons with rifampicin-resistant tuberculosis 
would emerge each year. Over the decade investigated there would be 1 056 000 additional persons 
cured of multidrug-resistant tuberculosis in the accelerated access scenario than in the baseline scenario.
Bull World Health Organ 2015;93:491–497| doi: http://dx.doi.org/10.2471/BLT.14.138925 495
Policy & practice




病。 其中仅有 20% 的人目前接受推荐的治疗方案，而















Accélérer l’accès à de nouveaux médicaments pour le traitement de la tuberculose multirésistante: une nécessité qui s’impose
On estime à un demi-million le nombre de personnes qui contractent 
chaque année la tuberculose multirésistante. De nos jours, à peine 
20% d’entre elles reçoivent le traitement recommandé, et seulement 
10% environ sont traitées avec succès. L’accès limité au traitement est 
probablement responsable de l’épidémie actuelle qui se propage par 
une transmission continue. L’amélioration de l’accès au traitement est 
freinée par les schémas thérapeutiques actuels, lesquels sont très longs, 
chers, mal tolérés et difficiles à gérer dans les régions où résident la 
plupart des patients. Bien que de nouveaux médicaments permettent 
d’améliorer les schémas thérapeutiques, les essais cliniques actuels 
et prévus ne laissent que peu d’espoir quant au développement de 
schémas qui favoriseraient l’amélioration rapide de l’accès au traitement. 
Dans cet article, nous soutenons que les essais cliniques sont certes 
nécessaires, mais qu’ils doivent être accompagnés d’une recherche 
opérationnelle de grande ampleur effectuée en temps voulu. Cette 
recherche permettrait d’obtenir des données programmatiques sur 
l’utilisation des nouveaux médicaments et schémas tout en améliorant 
l’accès à un traitement pouvant sauver des vies. Les risques perçus 
– tels que le développement rapide d’une résistance aux nouveaux 
médicaments – doivent être mis en balance avec les taux élevés de 
mortalité et de transmission qui se maintiendraient sans cela. Doubler 
l’accès au traitement et accroître son efficacité permettrait de sauver 
environ un million de vies au cours de la décennie à venir.
ملخص
احلاجة إىل التعجيل بتيسري سبل الوصول إىل األدوية اجلديدة لعالج السل املقاوم لألدوية املتعددة
يعانون  شخص  مليون  نصف  من  يقرب  ما  بأن  االعتقاد  يسود 
20 % من  من السل املقاوم لألدوية املتعددة سنوًيا. وبالكاد يتلقى 
10 % منهم  وحوايل  به،  املوىص  العالج  حالًيا  األشخاص  هؤالء 
عىل  احلصول  سبل  توفر  عدم  ولعل  بنجاح.  عالجهم  يتم  فقط 
املستمر  االنتقال  عرب  احلايل  الوباء  انتشار  إىل  يؤدي  ما  هو  العالج 
النظم  بسبب  العالج  تقديم  يف  التوسع  جهود  وتتعرقل  للعدوى. 
العالية وعدم  املدة والتكلفة  العالجية احلالية، والتي يشوهبا طول 
القدرة عىل حتملها، فضاًل عن صعوبة تقديمها يف األماكن التي يقيم 
فيها معظم املرىض. عىل الرغم من أن األدوية اجلديدة توفر فرصة 
لتحسني نظم العالج، فإن التجارب الرسيرية احلالية واملخطط هلا 
ال تقدم سوى القليل من األمل إلعداد نظم من شأهنا تيسري سبل 
التطوير العاجل لعملية التوسع يف تقديم العالج. ونحن إذ نطرح 
يف هذه املقالة رأينا القائل بأن التجارب الرسيرية – رغم رضورهتا 
نطاق واسع،  املناسب، وعىل  الوقت  استكامهلا يف  ينبغي  أنه  إال   –
املتعلقة  الرباجمية  البيانات  سيوفر  الذي  امليداين  البحث  وإجراء 
باستخدام أدوية ونظم عالج جديدة مع العمل يف نفس الوقت عىل 
تطوير سبل الوصول إىل العالج الالزم إلنقاذ احلياة. ويلزم موازنة 
– مثل التطور الرسيع ملقاومة األدوية اجلديدة  األخطار امللحوظة 
ستستمر  التي  العدوى  وانتقال  للوفيات  املرتفعة  املعدالت  مع   –
بخالف ذلك. ومن املمكن أن تؤدي مضاعفة فرص إتاحة العالج 
يقرب من مليون شخص  ما  إنقاذ  إىل  العالج  وزيادة نسب نجاح 
عىل مدى السنوات العرشة املقبلة.
approach in which access to new drugs 
is very restricted and scale-up is slowed. 
Flexibility and speed – combined with 
advocacy, political commitment, ad-
equate resources and pragmatism – are 
now required.  ■
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Резюме
Необходимость своевременного доступа к новым лекарственным препаратам для лечения 
туберкулеза с множественной лекарственной устойчивостью
Считается, что ежегодно туберкулезом с множественной 
лекарственной устойчивостью заболевает около полумиллиона 
человек. Из этих пациентов только 20% в настоящее время 
получают рекомендованное лечение, а успешно вылечиваются 
лишь около 10%. Недостаточный доступ к лечению является 
вероятной причиной нынешней эпидемии, которая продолжает 
распространяться.  Расширению масштабов лечения 
препятствуют существующие схемы лечения, которые являются 
продолжительными, дорогостоящими, плохо переносятся 
больными и которые трудно проводить в местах проживания 
большинства пациентов. Несмотря на то что в настоящее 
время планируются или уже проводятся испытания новых 
лекарственных препаратов, способных усовершенствовать 
схемы лечения, эти испытания вряд ли позволят сделать 
лечение более своевременным в широких масштабах. В данной 
статье мы приводим доводы в пользу того, что клинические 
испытания (безусловно, необходимые) должны сопровождаться 
своевременными, крупномасштабными, операционными 
исследованиями для получения программных данных о 
применении новых лекарственных препаратов и лечебных 
курсов, а также улучшения доступа к жизненно необходимому 
лечению. Предполагаемые риски, например стремительное 
развитие устойчивости к новым препаратам, необходимо 
соотносить с высоким уровнем заболеваемости и смертности, 
который в противном случае будет сохраняться. Если в 
следующем десятилетии лечение станет в два раза доступнее и 
его эффективность будет повышена, потенциально удастся спасти 
около одного миллиона жизней.
Resumen
La necesidad de acelerar el acceso a nuevos fármacos para la tuberculosis multirresistente
Se estima que alrededor de 500.000 personas al año desarrollan 
tuberculosis multirresistente. Apenas el 20% de estas personas recibe 
un tratamiento recomendado y solo el 10% se somete a un tratamiento 
eficaz. Probablemente la epidemia actual, a través de la transmisión 
continua, se deba al escaso acceso al tratamiento. La ampliación 
del tratamiento se ve obstaculizada por los regímenes terapéuticos 
actuales, que son prolongados, caros, producen intolerancia y son 
complicados de administrar en los lugares donde residen los pacientes. 
A pesar de que los nuevos fármacos son una oportunidad de mejorar 
los regímenes terapéuticos, los ensayos clínicos actuales y planificados 
no ofrecen demasiadas esperanzas para desarrollar regímenes que 
faciliten una ampliación del tratamiento a corto plazo. En este artículo 
sostenemos que los ensayos clínicos, mientras sea necesario, deberían 
ir acompañados de una investigación operativa oportuna a gran escala 
que proporcione información programática sobre el uso de los nuevos 
fármacos y regímenes, mientras mejora el acceso a un tratamiento que 
salvará vidas. Los riesgos, como el rápido desarrollo de la resistencia a 
nuevos fármacos, deberían equilibrarse frente a los altos niveles de 
mortalidad y transmisión que, de otro modo, continuarán existiendo. 
Duplicar el acceso al tratamiento y aumentar su éxito podría salvar 
alrededor de un millón de vidas en la próxima década.
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